We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Cryotherapy System Treats Superficial Bladder Cancer

By HospiMedica International staff writers
Posted on 06 Aug 2021
Print article
Image: The Vessi Medical bladder cryoablation system (Photo courtesy of Vessi Medical)
Image: The Vessi Medical bladder cryoablation system (Photo courtesy of Vessi Medical)
A minimally invasive cryoablation system offers a novel approach for the treatment of non muscle invasive bladder cancer (NMIBC).

The Vessi Medical (Misgav, Israel) minimally invasive cryotherapy solution is designed to provide a bladder-specific system that reduces the cost and eliminates complications associated with the current first-line treatment, transurethral resection of bladder tumor (TURBT). The Vessi system consists of a standalone console and a disposable probe inserted transurethrally that directs a targeted cryogenic spray specifically designed to balance between the ideal cooling temperature and pressure needed for targeted cell destruction inside the bladder.

“TURBT is an imprecise process that can result in healthy tissue being accidentally removed. It causes bleeding and sometimes perforation. Even worse, the scraping process can spread the cancer all over the place,” said Eyal Kochavi, CEO of Vessi Medical. “Vessi Medical’s cryotherapy is delivered as a spray, so physical contact with the bladder mucosa is minimized, while at the same time the risk of dispersing cancer cells through scraping is reduced.”

“The cryo procedure demonstrated an immediate change in the three-dimensional structure of the tumor. The freezing of the lesion was easily noticeable and it froze completely in only a few seconds, with similar quick thawing,” said Professor Gilad Amiel, MD, of Rambam Healthcare Campus (Haifa, Israel), commenting on successful completion of the first-in-human case. “We performed two cycles of freezing and thawing, to ensure apoptosis and necrosis of the lesion. We look forward to being able to offer cryotherapy for bladder papillary lesions as an office procedure without anesthesia, in the future.”

NMIBC is defined as a cancerous tumor on the surface of the inner lining of the bladder. Physical symptoms often include problems urinating, pain and blood in the urine, or sexual dysfunction; however, it may also affect mental health and lead to a significant decrease in quality of life.

Related Links:

Vessi Medical

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.